Clinical Trial Update: A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial assessing CC-122 in combination with nivolumab for unresectable hepatocellular carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• CC-122
• nivolumab (nivolumab)

Snippet

Sponsor: Celgene | Conditions: Carcinoma, Hepatocellular | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-05-11